Efficacy and Safety of Nusinersen in Children With Later-Onset Spinal Muscular Atrophy (SMA): End of Study Results From the Phase 3 CHERISH Study

Fiscal 3Q Investor Presentation

FY23 Full-Year Results Presentation

Healthcare Network P&L Statement and Expansion Projects

Accreditation and Quality Assurance Overview

Investment Highlights

Investor Presentation

IDEAYA Biosciences Interim IDE397 Phase 1 Clinical Data and Q1 2022 Corporate Update

BioAtla Investor Presentation Deck